{"id":"243209fb9ed1","type":"article","url":"https://hartvaat.nl/2026/05/27/inflammatoire-biomarkers-verbeteren-risicostratificatie-bij-perifeer-arterieel-v/","title":"Inflammatoire biomarkers verbeteren risicostratificatie bij perifeer arterieel vaatlijden","title_en":"Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Biomolecules","doi":"10.3390/biom16060789","source_url":"https://doi.org/10.3390/biom16060789","authors":["Andreea Tudurachi","Bogdan-Sorin Tudurachi","Larisa Anghel","Radu Andy Sascău","Mircea Ovanez Balasanian","Cristina Prisacariu","Amin Bazyani","Cristian Stătescu"],"significance":5,"published":"2026-07-28","source_date":"2026-05-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/cardiovasculair-risico-begrippen/"],"congress":"","summary_en":"This narrative review evaluates the prognostic value of classical and emerging inflammatory biomarkers in peripheral arterial disease (PAD). Elevated levels of markers such as CRP, GDF-15, galectin-3, and composite indices like the neutrophil-to-lymphocyte ratio are consistently associated with disease severity and adverse cardiovascular and limb outcomes. Incorporating these biomarkers into routine risk assessment may help identify high-risk patients who could benefit from targeted anti-inflammatory strategies, including colchicine and PCSK9 inhibitors, to mitigate residual cardiovascular risk.","created":"2026-07-20T01:18:51Z","updated":"2026-08-10T10:38:10Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze narratieve review samenvat de prognostische waarde van klassieke en opkomende inflammatoire biomarkers bij patiënten met perifeer arterieel vaatlijden. Markers als CRP, GDF-15, galectine-3 en indexen zoals de neutrofiel-lymfocytenratio correleren met ernst van de ziekte en het risico op MACE, MALE, restenose en amputatie. De integratie van deze biomarkers in de klinische praktijk kan helpen bij het verfijnen van risicostratificatie en het personaliseren van anti-inflammatoire therapieën, zoals colchicine en PCSK9-remmers, om residuair cardiovasculair risico te verlagen.","abstract_original":"Background: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis characterized by chronic inflammation, endothelial dysfunction, and high residual risk of major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs). This review aimed to summarize the prognostic role of inflammatory biomarkers in PAD and to discuss their therapeutic implications. Methods: A comprehensive narrative review was performed using PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library, focusing mainly on English-language studies published in recent years. Randomized trials, observational studies, systematic reviews, and meta-analyses evaluating inflammatory biomarkers and anti-inflammatory or vasculoprotective therapies in PAD were included. Results: Both classical and emerging inflammatory biomarkers were associated with PAD severity and adverse outcomes. C-reactive protein, fibrinogen, interleukins, tumor necrosis factor-α, myeloperoxidase, galectin-3, and growth differentiation factor-15 showed prognostic value for MACEs, MALEs, restenosis, amputation, and mortality. Among newer indices, the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, C-reactive protein-to-albumin ratio, and HALP (Hemoglobin, Albumin, Lymphocyte, and Platelet) score appear especially promising for risk stratification. Anti-inflammatory and pleiotropic therapies, including canakinumab, colchicine, statins, and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, may help reduce residual inflammatory risk. Conclusions: Inflammatory biomarkers may improve prognostic stratification and support more personalized management in PAD. Their integration into clinical practice could enhance limb preservation and long-term cardiovascular outcomes."}